{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:21:27Z","timestamp":1791498087542,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.steroids.2025.109675","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:03:36Z","timestamp":1755551016000},"page":"109675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Are dexamethasone implants a safe and effective breakthrough in uveitis treatment? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"223","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2025.109675_b0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/9781119782285.ch6","article-title":"Diseases of the uvea, uveitis, and recurrent uveitis","author":"Gilger","year":"2022","journal-title":"Equine Ophthalmology"},{"issue":"12","key":"10.1016\/j.steroids.2025.109675_b0010","doi-asserted-by":"crossref","DOI":"10.21037\/apm-21-3549","article-title":"Analysis of the clinical diagnosis and treatment of uveitis","volume":"10","author":"Wang","year":"2021","journal-title":"Annals of Palliative Medicine"},{"key":"10.1016\/j.steroids.2025.109675_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.4358","article-title":"Uveitis in adults: a Review","author":"Maghsoudlou","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2025.109675_b0020","series-title":"Archivos De La Sociedad Espa\u00f1ola De Oftalmolog\u00eda (English Edition)","article-title":"Infectious uveitis: Epidemiology, etiology, diagnostic test performance and treatment","author":"M\u00e9ndez-Rodr\u00edguez","year":"2025"},{"key":"10.1016\/j.steroids.2025.109675_b0025","first-page":"311","article-title":"Clinical Review of Uveitis: Part II. In Ophthalmology Board and FRCS Part 2 Exams","author":"Elobous","year":"2025","journal-title":"Eye Yield Clinical, Springer"},{"issue":"11","key":"10.1016\/j.steroids.2025.109675_b0030","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.3390\/jcm12113746","article-title":"Diagnosis, classification, and assessment of the underlying etiology of uveitis by artificial intelligence: a systematic review","volume":"12","author":"Jacquot","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.steroids.2025.109675_b0035","article-title":"Managing a patient with uveitis in the era of artificial intelligence: current approaches, emerging trends, and future perspectives","volume":"100082","author":"Rojas-Carabali","year":"2024","journal-title":"Asia-Pacific J. Ophthalmol."},{"key":"10.1016\/j.steroids.2025.109675_b0040","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.2147\/JIR.S288294","article-title":"Topical anti-inflammatory agents for non-infectious uveitis: current treatment and perspectives","author":"Balasubramaniam","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"8","key":"10.1016\/j.steroids.2025.109675_b0045","doi-asserted-by":"crossref","first-page":"18778","DOI":"10.3390\/ijms160818778","article-title":"New immunosuppressive therapies in uveitis treatment","volume":"16","author":"M\u00e9rida","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.steroids.2025.109675_b0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12016-014-8455-6","article-title":"The use of biologic therapies in uveitis","volume":"49","author":"Schwartzman","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"10.1016\/j.steroids.2025.109675_b0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40266-024-01143-8","article-title":"Oral Corticosteroids for Skin Disease in the older Population: Minimizing potential adverse Effects","volume":"41","author":"Sparling","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.steroids.2025.109675_b0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/OPTO.S492202","article-title":"Drug-Induced uveitis: patterns, pathogenesis and clinical implications","author":"Lu","year":"2025","journal-title":"Clin. Optom."},{"issue":"7","key":"10.1016\/j.steroids.2025.109675_b0065","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/pharmaceutics15071952","article-title":"A new era in ocular therapeutics: advanced drug delivery systems for uveitis and neuro-ophthalmologic conditions","volume":"15","author":"Wu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.steroids.2025.109675_b0070","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/pharmaceutics15051484","article-title":"Delivery systems in ocular retinopathies: the promising future of intravitreal hydrogels as sustained-release scaffolds","volume":"15","author":"Rafael","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.steroids.2025.109675_b0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/pharmaceutics12080703","article-title":"Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature","volume":"12","author":"Iovino","year":"2020","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.steroids.2025.109675_b0080","article-title":"A review of ten years of experience using dexamethasone intravitreal implants (Ozurdex) for uveitis","volume":"27","author":"Zeng","year":"2023","journal-title":"European Review for Medical & Pharmacological Sciences"},{"issue":"1","key":"10.1016\/j.steroids.2025.109675_b0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/bjophthalmol-2019-313991","article-title":"Safety of 6000 intravitreal dexamethasone implants","volume":"104","author":"Rajesh","year":"2020","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.steroids.2025.109675_b0090","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/09273948.2015.1070180","article-title":"The dexamethasone intravitreal implant for noninfectious uveitis: practice patterns among uveitis specialists","volume":"23","author":"Burkholder","year":"2015","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"1","key":"10.1016\/j.steroids.2025.109675_b0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"issue":"1","key":"10.1016\/j.steroids.2025.109675_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICOS and SPIDER: a Comparison Study of Specificity and Sensitivity in three Search Tools for Qualitative Systematic Reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv. Res."},{"issue":"7","key":"10.1016\/j.steroids.2025.109675_b0105","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.steroids.2025.109675_b0110","doi-asserted-by":"crossref","unstructured":"L.A. McGuinness, Riskofbias VISualization (robvis): An R package and Shiny web app for visualizing riskofbias assessments. Res Syn Meth 2020, n\/a (n\/a). DOI: 10.1002\/jrsm.1411 (acccessed 2020).","DOI":"10.1002\/jrsm.1411"},{"issue":"3","key":"10.1016\/j.steroids.2025.109675_b0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/17439760.2016.1262613","article-title":"Thematic analysis","volume":"12","author":"Clarke","year":"2017","journal-title":"J. Posit. Psychol."},{"key":"10.1016\/j.steroids.2025.109675_b0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/9781119099369.ch27","article-title":"Comprehensive meta\u2010analysis software","author":"Borenstein","year":"2022","journal-title":"Systematic Reviews in Health Research: Meta-Analysis in Context"},{"issue":"4","key":"10.1016\/j.steroids.2025.109675_b0125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jop.2016.0139","article-title":"Single Dexamethasone Intravitreal Implant in the Treatment of Noninfectious Uveitis","volume":"33","author":"Fr\u00e8re","year":"2017","journal-title":"J. Ocular Pharmacol. Therapeutics"},{"issue":"7","key":"10.1016\/j.steroids.2025.109675_b0130","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1089\/jop.2016.0035","article-title":"Response of postoperative and chronic uveitic cystoid macular edema to a dexamethasone-based intravitreal implant (Ozurdex)","volume":"32","author":"Garweg","year":"2016","journal-title":"J.Ocular Pharmacol. Therapeutics"},{"issue":"5","key":"10.1016\/j.steroids.2025.109675_b0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4274\/tjo.galenos.2019.81594","article-title":"Intravitreal dexamethasone implant in the treatment of non-infectious uveitis","volume":"49","author":"Hasanreiso\u011flu","year":"2019","journal-title":"Turkish J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.steroids.2025.109675_b0140","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s12325-019-00989-4","article-title":"Intravitreal dexamethasone implant for treatment of sarcoidosis-related uveitis","volume":"36","author":"Kim","year":"2019","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1016\/j.steroids.2025.109675_b0145","doi-asserted-by":"crossref","DOI":"10.3892\/mi.2023.99","article-title":"Dexamethasone intravitreal implant for macular edema and some other rare indications in uveitis","volume":"3","author":"K\u00f6ksald\u0131","year":"2023","journal-title":"Med. Int."},{"issue":"3","key":"10.1016\/j.steroids.2025.109675_b0150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/IAE.0000000000002901","article-title":"Uveitis treated with dexamethasone implant","volume":"41","author":"Mathis","year":"2021","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"10.1016\/j.steroids.2025.109675_b0155","doi-asserted-by":"crossref","unstructured":"Palla, S.; Biswas, J.; Nagesha, C. K. Efficacy of OzurDexamethasone implant in treatment of noninfectious intermediate uveitis. Indian Journal of Ophthalmology 2015, 63 (10), 767-770. DOI: 10.4103\/0301-4738.171505 (acccessed 2022).","DOI":"10.4103\/0301-4738.171505"},{"issue":"7","key":"10.1016\/j.steroids.2025.109675_b0160","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/09273948.2018.1424342","article-title":"Safety and efficacy of intravitreal dexamethasone implant for refractory uveitic macular edema in adults and children","volume":"26","author":"Ratra","year":"2018","journal-title":"Ocular Immunol. Inflammation"},{"key":"10.1016\/j.steroids.2025.109675_b0165","doi-asserted-by":"crossref","unstructured":"N. Tukenmez Dikmen, Intravitreal Dexamethasone Implant Results in the Treatment of Non-Infectious Uveitis. Northern Clinics of Istanbul 2021. DOI: 10.14744\/nci.2021.92342 (accessed 2021).","DOI":"10.14744\/nci.2021.92342"},{"key":"10.1016\/j.steroids.2025.109675_b0170","doi-asserted-by":"crossref","unstructured":"Zarranz-Ventura, J.; Carre\u00f1o, E.; Johnston, R. L.; Mohammed, Q.; Ross, A. H.; Barker, C.; Fonollosa, A.; Joseba, A.; Pelegrin, L.; Adan, A.; et al. Multicenter Study of Intravitreal Dexamethasone Implant in Noninfectious Uveitis: Indications, Outcomes, and Reinjection Frequency. American Journal of Ophthalmology 2014, 158 (6), 1136-1145.e1135. DOI: 10.1016\/j.ajo.2014.09.003 (acccessed 2025).","DOI":"10.1016\/j.ajo.2014.09.003"},{"issue":"7","key":"10.1016\/j.steroids.2025.109675_b0175","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0b013e31827e247b","article-title":"Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients","volume":"33","author":"Ad\u00e1n","year":"2013","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.steroids.2025.109675_b0180","first-page":"501","article-title":"A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex)","volume":"29","author":"Arcinue","year":"2013","journal-title":"Intravitreal Implants in Uveitis."},{"issue":"3","key":"10.1016\/j.steroids.2025.109675_b0185","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/09273948.2020.1826534","article-title":"Effectiveness of the dexamethasone implant in lieu of oral corticosteroids in intermediate and posterior uveitis requiring immunosuppression","volume":"30","author":"Berkenstock","year":"2020","journal-title":"Ocular Immunol. Inflammation"},{"issue":"2","key":"10.1016\/j.steroids.2025.109675_b0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaapos.2013.11.014","article-title":"Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis","volume":"18","author":"Bratton","year":"2014","journal-title":"J. American Assoc. Pediatric Ophthalmol. Strabismus"},{"key":"10.1016\/j.steroids.2025.109675_b0195","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/OPTH.S393662","article-title":"Treatment of non-infectious posterior uveitis with dexamethasone intravitreal implants in a real-world setting","volume":"17","author":"Butt","year":"2023","journal-title":"Clin. Ophthalmol."},{"issue":"6","key":"10.1016\/j.steroids.2025.109675_b0200","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/09273948.2015.1042167","article-title":"Intravitreal dexamethasone implant for treatment of refractory beh\u00e7et posterior uveitis: one-year follow-up results","volume":"23","author":"Co\u015fkun","year":"2015","journal-title":"Ocular Immunol. Inflammation"},{"issue":"3","key":"10.1016\/j.steroids.2025.109675_b0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.18240\/ijo.2023.03.05","article-title":"Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract","volume":"16","author":"Deng","year":"2023","journal-title":"Int. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.steroids.2025.109675_b0210","first-page":"415","article-title":"Intravitreal dexamethasone implant as an adjunct weapon for severe and refractory uveitis in Beh\u00e7et's Disease","volume":"19","author":"Fabiani","year":"2017","journal-title":"The Israel Medical Association Journal : IMAJ"},{"issue":"9","key":"10.1016\/j.steroids.2025.109675_b0215","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/IAE.0000000000001001","article-title":"Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis","volume":"36","author":"Fonollosa","year":"2016","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.steroids.2025.109675_b0220","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/IAE.0000000000000515","article-title":"Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema","volume":"35","author":"Khurana","year":"2015","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.steroids.2025.109675_b0225","doi-asserted-by":"crossref","first-page":"317","DOI":"10.18240\/ijo.2021.02.21","article-title":"Utilizing dexamethasone intravitreal implant to control postoperative inflammation in refractory uveitis undergoing cataract surgery","volume":"14","author":"Li","year":"2021","journal-title":"Int. J. Ophthalmol."},{"issue":"9","key":"10.1016\/j.steroids.2025.109675_b0230","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/ceo.13611","article-title":"Intravitreal dexamethasone implants for non-infectious uveitis","volume":"47","author":"McCartney","year":"2019","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"6","key":"10.1016\/j.steroids.2025.109675_b0235","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/jop.2015.0009","article-title":"The use of ozurdex (dexamethasone intravitreal implant) during anterior segment surgery in patients with chronic recurrent uveitis","volume":"31","author":"Ragam","year":"2015","journal-title":"J. Ocular Pharmacol. Therapeutics"},{"key":"10.1016\/j.steroids.2025.109675_b0240","doi-asserted-by":"crossref","unstructured":"Sella, R.; Oray, M.; Friling, R.; Umar, L.; Tugal-Tutkun, I.; Kramer, M. Dexamethasone intravitreal implant (Ozurdex\u00ae) for pediatric uveitis. Graefe's Archive for Clinical and Experimental Ophthalmology 2015, 253 (10), 1777-1782. DOI: 10.1007\/s00417-015-3124-x (acccessed 2025).","DOI":"10.1007\/s00417-015-3124-x"},{"key":"10.1016\/j.steroids.2025.109675_b0245","doi-asserted-by":"crossref","unstructured":"Tsang, A. C.; Virgili, G.; Abtahi, M.; Gottlieb, C. C. Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Chronic Non-infectious Uveitis. Ocular Immunology and Inflammation 2016, 25 (5), 690-697. DOI: 10.3109\/09273948.2016.1160130 (acccessed 2022).","DOI":"10.3109\/09273948.2016.1160130"},{"key":"10.1016\/j.steroids.2025.109675_b0250","doi-asserted-by":"crossref","unstructured":"Acharya, N. R.; Vitale, A. T.; Sugar, E. A.; Holbrook, J. T.; Burke, A. E.; Thorne, J. E.; Altaweel, M. M.; Kempen, J. H.; Jabs, D. A. Intravitreal Therapy for Uveitic Macular Edema\u2014Ranibizumab versus Methotrexate versus the Dexamethasone Implant. Ophthalmology 2023, 130 (9), 914-923. DOI: 10.1016\/j.ophtha.2023.04.011 (acccessed 2024).","DOI":"10.1016\/j.ophtha.2023.04.011"},{"key":"10.1016\/j.steroids.2025.109675_b0255","doi-asserted-by":"crossref","unstructured":"Elhamaky, T. Long-term efficacy of dexamethasone intravitreal implant in the treatment of Vogt-Koyanagi-Harada disease relapsing posterior uveitis. Indian Journal of Ophthalmology 2022, 70 (7), 2465-2465. DOI: 10.4103\/ijo.ijo_260_22 (acccessed 2024).","DOI":"10.4103\/ijo.IJO_260_22"},{"issue":"8","key":"10.1016\/j.steroids.2025.109675_b0260","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1080\/09273948.2018.1524498","article-title":"Efficacy of intravitreal dexamethasone implant in patients of uveitis undergoing cataract surgery","volume":"27","author":"Gupta","year":"2018","journal-title":"Ocular Immunol. Inflammation"},{"key":"10.1016\/j.steroids.2025.109675_b0265","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2015.09.036","article-title":"Outcome of Treating Pediatric Uveitis with Dexamethasone Implants","volume":"161","author":"Tomkins-Netzer","year":"2016","journal-title":"Am. J. Ophthalmol."},{"issue":"15","key":"10.1016\/j.steroids.2025.109675_b0270","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.biomaterials.2005.12.021","article-title":"Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery","volume":"27","author":"Kim","year":"2006","journal-title":"Biomaterials"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X25001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X25001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:00:40Z","timestamp":1760155240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X25001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"alternative-id":["S0039128X25001163"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2025.109675","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are dexamethasone implants a safe and effective breakthrough in uveitis treatment? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2025.109675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109675"}}